References

10.1016/j.hoc.2009.03.006

10.1016/j.hoc.2009.03.006 · External reference

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993

10.1200/jco.1999.17.7.2105 · 1999 · External reference

10.1186/1479-5876-10-85

10.1186/1479-5876-10-85 · External reference

10.1158/1535-7163.mct-10-0799

10.1158/1535-7163.mct-10-0799 · External reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

10.1056/nejmoa1002011 · 2010 · External reference

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma

10.1200/jco.2011.29.15_suppl.8509 · 2011 · External reference

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

10.1056/nejmoa1103782 · 2011 · External reference

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

10.1200/jco.2010.28.15_suppl.8503 · 2010 · External reference

BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma

2011 · External reference

Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial

2012 · External reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

10.1038/nature09626 · 2010 · External reference

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

10.1158/2159-8290.cd-13-0642 · 2014 · External reference

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

10.1200/jco.2010.33.2312 · 2011 · External reference

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

2011 · External reference

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study

10.1093/annonc/mdx339 · 2017 · External reference

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

10.1016/j.ejca.2019.10.033 · 2020 · External reference

Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

10.1200/jco.2012.43.5966 · 2013 · External reference

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

10.1056/nejmoa1203421 · 2012 · External reference

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

10.1056/nejmoa1210093 · 2012 · External reference

Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma

2014 · External reference

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

10.1016/s1470-2045(16)30122-x · 2016 · External reference

5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: Extended follow-up of the coBRIM study

10.1158/1078-0432.ccr-21-0809 · 2021 · External reference

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial

2015 · External reference

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

10.1056/nejmoa1412690 · 2015 · External reference

Somatic activation of KIT in distinct subtypes of melanoma

10.1200/jco.2006.06.2984 · 2006 · External reference

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network

10.1016/j.jid.2017.07.839 · 2018 · External reference

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)

10.1002/cncr.30663 · 2017 · External reference

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma

2015 · External reference

Treatment of NRAS-mutant melanoma

10.1007/s11864-015-0330-z · 2015 · External reference

Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma

10.1158/1078-0432.ccr-17-0723 · 2018 · External reference

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

10.1056/nejmoa1805131 · 2018 · External reference

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial

10.1016/j.annonc.2021.07.008 · 2021 · External reference

Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long- term Follow-up

10.1158/1078-0432.ccr-13-1411 · 2014 · External reference

Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans(DFSP)

10.1158/1078-0432.ccr-15-1243 · 2016 · External reference

PD-1/PD-L1 pathway: current researches in cancer

2020 · External reference

The blockade of immune checkpoints in cancer immunotherapy

10.1038/nrc3239 · 2012 · External reference

Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma

10.1200/jco.2014.56.2736 · 2015 · External reference

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials

10.1177/1758835920937612 · 2020 · External reference

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

10.1056/nejmoa1412082 · 2015 · External reference

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial

10.1016/s1470-2045(15)70076-8 · 2015 · External reference

Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

10.1200/jco.2016.71.8023 · 2018 · External reference

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial

10.1016/s1470-2045(15)00083-2 · 2015 · External reference

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

10.1093/annonc/mdw379.02 · 2016 · External reference

Pembrolizumab versus Ipilimumab in Advanced Melanoma

10.1056/nejmoa1503093 · 2015 · External reference

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

10.1016/s0140-6736(17)31601-x · 2017 · External reference

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

10.1200/jco.21.02229 · 2022 · External reference

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

10.1056/nejmoa2109970 · 2022 · External reference

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

10.1056/nejmoa1709684 · 2017 · External reference

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial

10.1016/s1470-2045(15)70122-1 · 2015 · External reference

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

10.1016/j.ejca.2019.07.001 · 2019 · External reference

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

10.1056/nejmoa1802357 · 2018 · External reference

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

10.1016/s1470-2045(21)00065-6 · 2021 · External reference

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

10.1056/nejmoa1709030 · 2017 · External reference

Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials

10.1177/17588359221083052 · 2022 · External reference

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

10.1038/s41591-018-0198-0 · 2018 · External reference

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

10.1016/s1470-2045(19)30151-2 · 2019 · External reference

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

10.1056/nejmoa2211437 · 2023 · External reference

Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events

10.1136/jitc-2021-002435 · 2021 · External reference

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology

2022 · External reference

Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma

10.1200/jco.2022.40.16_suppl.9501 · 2022 · External reference

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

10.1056/nejmoa1406498 · 2014 · External reference

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

10.1126/science.aad0095 · 2015 · External reference

Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis

10.1158/1078-0432.ccr-20-0458 · 2020 · External reference

Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice

10.18632/oncotarget.5950 · 2015 · External reference

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade

10.1172/jci91190 · 2017 · External reference

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

10.1038/s41591-020-01211-7 · 2021 · External reference

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

2023 · External reference

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy

10.1158/1078-0432.ccr-21-1283 · 2021 · External reference

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1–based immunotherapy

10.1158/1078-0432.ccr-18-2795 · 2019 · External reference

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma

10.1038/s41591-021-01623-z · 2022 · External reference

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

10.1016/j.medj.2022.12.007 · 2023 · External reference

Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens

10.1186/s12967-023-04172-w · 2023 · External reference

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events

10.3390/cancers15051629 · 2023 · External reference

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s0140-6736(20)30934-x · 2020 · External reference

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

10.1016/s1470-2045(22)00687-8 · 2023 · External reference

KEYNOTE-022 part 3: A randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

10.1136/jitc-2020-001806 · 2020 · External reference

Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology

10.1245/s10434-017-6266-8 · 2018 · External reference

Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy

10.1097/ppo.0000000000000608 · 2022 · External reference

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma

10.4049/jimmunol.138.3.989 · 1987 · External reference

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report [see comments]

10.1056/nejm198812223192527 · 1988 · External reference

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

10.1084/jem.20050732 · 2005 · External reference

Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer

10.1016/s0140-6736(89)91609-7 · 1989 · External reference

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

10.1093/jnci/86.15.1159 · 1994 · External reference

A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma

10.1097/00002371-200205000-00007 · 2002 · External reference

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

10.1200/jco.2005.00.240 · 2005 · External reference

Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens

10.1200/jco.2008.16.5449 · 2008 · External reference

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

10.1158/1078-0432.ccr-11-0116 · 2011 · External reference

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma

10.1097/cji.0b013e31826e8f5f · 2012 · External reference

Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies

10.1158/1078-0432.ccr-13-0380 · 2013 · External reference

Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma

10.1200/jco.2016.66.7220 · 2016 · External reference

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1

10.1200/jco.2019.37.15_suppl.2518 · 2019 · External reference

Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma

10.1158/1078-0432.ccr-21-1171 · 2021 · External reference

Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma

10.1158/1078-0432.ccr-21-4499 · 2022 · External reference

Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma

10.1158/1078-0432.ccr-17-2267 · 2018 · External reference

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

10.1200/jco.21.00612 · 2021 · External reference

10.1136/jitc-2022-005755

10.1136/jitc-2022-005755 · 2022 · External reference